Liposomal formulations of amidine substituted beta-lactam compounds for use in the treatment of bacterial infections

A technology of liposomes and compounds, applied in the field of liposome β-lactam preparations

Inactive Publication Date: 2019-07-05
AICURIS ANTI INFECTIVE CURES
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, neither strong acidic pH nor acetoni

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liposomal formulations of amidine substituted beta-lactam compounds for use in the treatment of bacterial infections
  • Liposomal formulations of amidine substituted beta-lactam compounds for use in the treatment of bacterial infections
  • Liposomal formulations of amidine substituted beta-lactam compounds for use in the treatment of bacterial infections

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0084] 1. Preparation of Liposomes

[0085]All liposomal formulations were prepared by the thin film hydration method. Briefly, an accurately weighed amount of 55 / 45 (mol) DSPC / Chol was dissolved in a round bottom flask with chloroform, and a film was produced at 40°C under reduced pressure. After complete removal of the organic solvent, the membrane was hydrated with one of the following buffers: 300 mM ammonium sulfate; 150 mM sodium acetate; 120 mM calcium acetate, or 0.9% NaCl (used as a negative control) and HEPES / saline buffer at pH 7.4 (HBS) (used as a negative control) at a final concentration of 60 mM lipid.

[0086] After one hour of hydration at 65°C (the membrane was completely removed from the flask wall), a Lipexthermobarrel extruder equipped with polycarbonate membranes of various pore sizes (400, 200 and 100 nm) was used The liposomes were extruded so as to reach a final size of 130-150 nm with PdI<0.100. In this size range, maximum theoretical encapsulation...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides new and effective liposomal fomiulations for the administration of beta-lactams.

Description

technical field [0001] The present invention relates to liposomal β-lactam formulations, encapsulation of such β-lactams within liposomes for drug delivery purposes and the use of such formulations in the treatment and prophylaxis of bacterial infections. Background technique [0002] The present invention relates to novel β-lactam formulations, their preparation and use. In particular, the present invention relates to novel β-lactam compounds, which are amidine-substituted monocyclic compounds useful as antimicrobial agents, and their encapsulation in liposomes as drug delivery systems. β-lactam derivatives. [0003] Public health experts and officials consider the emergence and spread of antibiotic resistant bacteria to be one of the major public health problems of the 21st century. While not a new phenomenon in itself, the spread of antibiotic-resistant bacteria has reached unprecedented levels. Although the majority of drug-resistant isolates continue to emerge in the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/427A61K9/127A61P31/04
CPCA61K9/127A61K31/427A61P31/04Y02A50/30
Inventor 约戈什瓦尔·巴克哈夫
Owner AICURIS ANTI INFECTIVE CURES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap